FLGT - Company ID 0001674930
The table below shows Fulgent Genetics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $85.39M | $71.14M | $84.07M | $81.80M | $73.46M | $71.74M |
| Cost of revenue | $59.71M | $49.65M | $48.56M | $47.37M | $45.12M | $44.97M |
| Gross profit | $25.68M | $21.49M | $35.51M | $34.44M | $28.35M | $26.77M |
| R&D | $14.55M | $14.18M | $13.86M | $13.48M | $12.39M | $11.78M |
Fulgent Genetics, Inc. reported annual revenue of $322.67M for fiscal year 2025. That is up 13.8% from $283.47M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $18.28M (FY 2016) to $322.67M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $27.20M | $27.68M | $23.34M | $26.39M | $25.29M | $20.95M |
| Operating income | -$36.07M | -$34.62M | -$15.35M | -$19.71M | -$19.80M | -$17.08M |
| Income tax | $29.00K | -$704.00K | -$683.00K | -$2.26M | $176.00K | -$3.84M |
| Net income | -$29.53M | -$24.83M | -$6.61M | -$18.96M | -$11.53M | -$14.65M |
| EPS (diluted) | - | - | - | - | - | - |